AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.

Employees

Sector

Pharmaceuticals

More about the company

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - OTC Markets Other stock markets 10:27:29 28/05/2026 pm IST			5-day change	1st Jan Change
1.120 ^USD	-.--%		-.--%	-22.76%

01/07	AB Science, successful private placement
29/06	AB Science Reports Completion of Step 3 of Phase 1 Evaluating Combination of Ab8939 with Venetoclax for Treatment of Refractory or Relapsed Acute Myeloid Leukemia	CI

Market Cap	5.87Cr 6.72Cr 5.39Cr 5.03Cr 9.53Cr 639.59Cr 9.69Cr 65Cr 25Cr 313.71Cr 25Cr 25Cr 1.08TCr	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	5.87Cr 6.72Cr 5.39Cr 5.03Cr 9.53Cr 639.59Cr 9.69Cr 65Cr 25Cr 313.71Cr 25Cr 25Cr 1.08TCr	EV / Sales 2026 *	48.9x	EV / Sales 2027 *	45.2x
Free-Float	67.54%	Yield 2026 *	-	Yield 2027 *	-

01/07	AB Science, successful private placement
29/06	AB Science Reports Completion of Step 3 of Phase 1 Evaluating Combination of Ab8939 with Venetoclax for Treatment of Refractory or Relapsed Acute Myeloid Leukemia	CI
29/06	AB Science completes Step 3 of a Phase 1 study
18/06	AB Science Secures US Patent for Prostate Cancer Therapy	MT
18/06	AB Science Secures New U.S. Patent for Masitinib
17/06	AB Science Patent For Masitinib In The Treatment Of Metastatic Castrate Resistant Prostate Cancer Formally Granted In The United States With Protection Until 2042	CI
10/06	AB Science presents new data on Masitinib
18/05	AB Science S.A. announced that it has received $2.989368 million in funding	CI
13/05	AB Science S.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04/05	AB Science S.A. announced that it expects to receive $2.989368 million in funding	CI
29/04	Airbus, Pernod Ricard, Sopra Steria, TotalEnergies, TP... stocks to watch today in Paris
29/04	AB Science announces successful capital increase
28/04	Air Liquide, Nexans, AB Science... stocks to watch today in Paris

01/07	AB Science announces the successful completion of a EUR 2.3 million private placement	GL
29/06	AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML	GL
29/06	AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML	AQ
17/06	AB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 2042	GL
09/06	AB Science is invited to present at the 2026 ENCALS annual meeting the survival data from masitinib clinical program in ALS	GL

AB Science Share Price OTC Markets

Stocks

ABSCF

FR0010557264

Pharmaceuticals

Valuation: AB Science

Chart: AB Science

Latest news : AB Science

Last Transcript: AB Science

Press Releases: AB Science

News in other languages: AB Science

Quotes and Performance

Course Extremes

Managers and Directors: AB Science

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Income Statement and Estimates

Quarterly revenue - Rate of surprise

01/07	AB Science : Résultats de l'Assemblée Générale Mixte du 30 juin 2026
01/07	Bourse : Schneider se renforce dans l'IA, Air Liquide investit pour SK Hynix, Nike déçoit
01/07	AB Science, succès d'un placement privé
01/07	AB Science annonce le succès d’un placement privé de 2,3 millions d’euros
01/07	La Bourse s'habitue à tout

Current year	1.12	1.37
1 year	1.12	1.45
3 years	0	4.46
5 years	0	18.78
10 years	0	26.7

Manager	Title	Age	Since
Alain Moussy CEO	Chief Executive Officer	-	11/07/2001
Laurent Guy DFI	Director of Finance/CFO	-	20/11/2009
Christian Fassotte CTO	Chief Tech/Sci/R&D Officer	-	01/04/2018

Director	Title	Age	Since
Alain Moussy CHM	Chairman	-	11/07/2001
Patrick Moussy BRD	Director/Board Member	-	20/09/2011
Cécile de Guillebon BRD	Director/Board Member	64	27/06/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AB SCIENCE	-.--%	-.--%	-	-	6.8Cr
MERCK & CO., INC.	+3.34%	+3.28%	+57.25%	+12.28%	31TCr
MERCK KGAA	+2.08%	+0.34%	+30.88%	-2.67%	7.16TCr
HALOZYME THERAPEUTICS, INC.	+3.17%	+9.38%	+47.57%	+120.27%	913.44Cr
KYOWA KIRIN CO., LTD.	+1.54%	+4.81%	+7.14%	-0.50%	826.58Cr
SK BIOPHARMACEUTICALS CO., LTD.	-0.12%	-2.26%	-5.87%	+7.05%	437.88Cr
BETTA PHARMACEUTICALS CO., LTD.	-1.10%	+8.65%	+18.27%	+39.91%	420.78Cr
YUHAN CORPORATION	-0.57%	-1.68%	-34.24%	+21.86%	339.11Cr
SUPERNUS PHARMACEUTICALS, INC.	+1.35%	+7.37%	+49.83%	+59.85%	275.17Cr
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-1.31%	+4.21%	+17.92%	-21.65%	224.36Cr
Average	+0.84%	+6.16%	+20.97%	+26.27%	4.62TCr
Weighted average by Cap.	+2.93%	+3.55%	+49.43%	+12.26%

	2026 *	2027 *
Net sales	12L 13.73L 11.02L 10.28L 19.48L 13Cr 19.81L 1.33Cr 51.42L 6.41Cr 51.57L 50.44L 22Cr	13L 14.88L 11.94L 11.13L 21.1L 14Cr 21.46L 1.44Cr 55.7L 6.95Cr 55.86L 54.65L 24Cr
Net income	-	-
Net Debt	-	-